P1437 - Impact of Changes in Patient-Reported Symptoms of Irritable Bowel Syndrome with Diarrhea on Health-Related Quality of Life Among Patients Identified in Real-World Clinical Practice

Monday, October 25, 2021

10:30 AM – 4:15 PM PT

Location: Shoreline Exhibit Hall

Has Audio

Presenting Author(s)

Kate Burslem, MSc

Abbvie
Madison, NJ, United States

Jalpa Doshi, PhD¹, Steven Marcus, PhD², Jonathan Rosenberg, MD³, Lawrence Kosinski, MD, MBA⁴, Jessica Abel, MPH⁵, Kate Burslem, MSc⁶
¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ²School of Social Policy and Practice, University of Pennsylvania, Philadelphia, PA; ³Illinois Gastroenterology Group, Elgin, IL; ⁴SonarMD, Chicago, IL; ⁵AbbVie Inc., Madison, NJ; ⁶Abbvie, Madison, NJ

Introduction: Irritable bowel syndrome with diarrhea (IBS-D) is a chronic gastrointestinal disorder with significant impact on health-related quality of life (HRQoL). Bothersome abdominal symptoms are common in IBS-D, but their impact on HRQoL is unclear. The present analyses examined how changes in stool/abdominal symptoms impact HRQoL in patients with IBS-D.

Methods: Prospective, longitudinal data were collected via a custom, mobile version of the SonarMD IBS-D patient engagement platform. Participants were identified as having IBS-D via a clinical decision support tool within SonarMD. Participants were followed for up to 12 months and completed monthly symptom assessments of: loose stool frequency (“0” or “1–10+” in the past 24 hours), days experiencing ≥ 1 urgent trip to the toilet (“0” or “1–7” in the past 7 days), average abdominal pain (“none/mild” or “moderate/severe” over the past 7 days), and well-being due to IBS symptoms (“well” [0=well or 1=slightly under par] or “not well” [2=poor; 3=very poor; 4=terrible] over the past 7 days). A binary logit estimation within a fixed effects model framework was used to examine the impact of changes in IBS-D symptoms on changes in HRQoL while controlling for sociodemographic and clinical characteristics.

Results: 111 participants were enrolled in the platform and completed a baseline survey. Mean age was 55.1 years; 73% were female; 91% were non-Hispanic white. Mean IBS-D symptom duration was 16.8 years, and mean number of years seeing a provider for IBS-D was 10.1. Total number of participant-months was 1298. For participants reporting a change from 0 loose stool/day to ≥ 1 loose stool(s)/day, their odds of being “not well” increased by 3.2 times (odds ratio [OR], 3.24; 95% CI, 1.64–6.37; p = 0.001). For participants reporting a change from experiencing no urgency to experiencing ≥ 1 day with urgent trips to the toilet in the past 7 days, their odds of being “not well” increased by 3.5 times (OR, 3.50; 95% CI, 1.55–7.93; p = 0.003). Those reporting a change from no/mild pain to moderate/severe abdominal pain in the past 7 days had an increase in odds of being “not well” of 5.2 times (OR, 5.23; 95% CI, 3.09–8.84; p = 0.000).

Discussion: A worsening in any IBS-D symptom (loose stool, urgency, abdominal pain) resulted in a significant worsening in HRQoL (measured as well-being). These results may help patients and providers with the appropriate management of IBS-D symptoms to improve overall patient HRQoL.

Editorial assistance by Complete HealthVizion.

Disclosures:

Jalpa Doshi: AbbVie – Grant/Research Support. Allergan plc (now AbbVie) – Advisory Committee/Board Member. Allergan plc (now AbbVie) – Consultant. Biogen – Grant/Research Support. Janssen – Grant/Research Support. Pfizer – Grant/Research Support. PhRMA – Grant/Research Support. Regeneron – Grant/Research Support. Sanofi – Grant/Research Support. Sanofi – Advisory Committee/Board Member. Sanofi – Consultant. Shire – Consultant. Shire – Advisory Committee/Board Member. Vertex – Advisory Committee/Board Member. Vertex – Consultant.

Steven Marcus: AbbVie Inc. – Consultant.

Jonathan Rosenberg: AbbVie Inc. – Speaker's Bureau. Coral Genomics – Advisory Committee/Board Member. Nestlé – Speaker's Bureau. Salix – Speaker's Bureau.

Lawrence Kosinski: SonarMD – Other Financial or Material Support, Owner and director.

Jessica Abel: AbbVie Inc. – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).

Kate Burslem: AbbVie Inc. – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds).

Jalpa Doshi, PhD¹, Steven Marcus, PhD², Jonathan Rosenberg, MD³, Lawrence Kosinski, MD, MBA⁴, Jessica Abel, MPH⁵, Kate Burslem, MSc⁶. P1437 - Impact of Changes in Patient-Reported Symptoms of Irritable Bowel Syndrome with Diarrhea on Health-Related Quality of Life Among Patients Identified in Real-World Clinical Practice, ACG 2021 Annual Scientific Meeting Abstracts. Las Vegas, Nevada: American College of Gastroenterology.